Stock NUE NUEVOLUTION AB (PUBL)
Add to a list
To use this feature you must be a member
Log inSign up

All News Nuevolution AB (publ)

Equities

NUE

SE0007730650

Delayed Nasdaq Stockholm
Other stock markets
 		5-day change 1st Jan Change
- SEK -.--% Intraday chart for Nuevolution AB (publ) -0.31% +90.59%
2019 Amgen Inc. completed the acquisition of Nuevolution AB (OM:NUE) from Industrifonden, Skandinaviska Enskilda Banken AB (publ.) (OM:SEB A), Sunstone LSV Fund I K/S, SEB-Stiftelsen, Skandinaviska Enskilda Bankens Pensionsstiftelse, S-E-Bankens Utvecklingsstiftelse and others. CI
2019 Nuevolution AB Reports Earnings Results for the First Quarter Ended of March 2019 CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Amgen Inc. completed the acquisition of Nuevolution AB (OM:NUE) from Industrifonden, Skandinaviska Enskilda Banken AB (publ.) (OM:SEB A), Sunstone LSV Fund I K/S, SEB-Stiftelsen, Skandinaviska Enskilda Bankens Pensionsstiftelse, S-E-Bankens Utvecklingsstiftelse and others.
CI
Nuevolution AB Reports Earnings Results for the First Quarter Ended of March 2019
CI
Amgen Inc. made an offer to acquire Nuevolution AB (OM:NUE) from Industrifonden, Skandinaviska Enskilda Banken AB (publ.) (OM:SEB A), Sunstone LSV Fund I K/S, SEB-Stiftelsen, Skandinaviska Enskilda Bankens Pensionsstiftelse, S-E-Bankens Utvecklingsstiftelse and others for SEK 1.6 billion.
CI
Nuevolution's BET-BD1 Selective Inhibitor and Candidate Compound, NUE20798, Shows Positive Effect on Disease Scoring and Biomarker Levels in an Atopic Dermatitis Mouse Model
CI
Nuevolution publ : Svenska & English
PU
Nuevolution publ : Svenska & Engslish
PU
Nuevolution publ : AGM Proxy form UK
PU
Nuevolution publ : Corporate Governance Report 2018
PU
Nuevolution AB Announces Audited Consolidated and Parent Earnings Results for the Year Ended December 31, 2018
CI
Nuevolution publ : EDISON MARCH 2019
PU
Nuevolution AB Publ Reports Earnings Results for the Fourth Quarter Ended December 31, 2018
CI
Nuevolution AB Announces First Animal Preclinical Data
CI
Nuevolution AB Announces Earnings Results for the Third Quarter and Nine Months Ended September 30, 2018
CI
Nuevolution to Present Data from its Discovery Program Directed at Targeting the Key Disease Inflammatory Signaling Molecule, Interleukin-17A (IL-17A)
CI
Nuevolution publ : EDISON SEPTEMBER 2018
PU
Nuevolution publ : REDEYE SEPTEMBER 2018
PU
Nuevolution AB Announces Executive Changes
CI
Nuevolution AB Announces Consolidated and Parent Earnings Results for the Second Quarter and Six Months Ended June 30, 2018
CI
Nuevolution publ : INTERIM REPORT Q2 2018
PU
Nuevolution publ : OFFENTLIGGÖR ATT IDENTITETEN FÖR SITT “CYTOKIN X”-PROGRAM ÄR INTERLEUKIN IL-17A OCH INLEDER ARBETET ATT SÖKA PARTNERSKAP FÖR SITT PROGRAM FÖR SMÅMOLEKYL IL-17A-IHÄMMARE RIKTAT MOT INFLAMMATORISKA SJUKDOMAR OFFENTLIGGÖR ATT IDENTITETEN FÖR SITT “CYTOKIN X”-PROGRAM ÄR INTERLEUKIN IL-17A OCH INLEDER ARBETET ATT SÖKA PARTNERSKAP FÖR SITT PROGRAM FÖR SMÅMOLEKYL IL-17A-IHÄMMARE RIKTAT MOT I
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NUE Stock
  4. News Nuevolution AB (publ)